The global Viral Vector-Based Cell & Gene Therapy CDMO market size is predicted to grow from US$ 154 million in 2025 to US$ 326 million in 2031; it is expected to grow at a CAGR of 13.4% from 2025 to 2031.

Viral vector-based cell and gene therapy CDMO refers to a contract research and development and production organization (CDMO) that focuses on providing professional R&D and production services for viral vector-based cell and gene therapy products to biopharmaceutical companies. These services cover everything from the design and optimization of viral vectors to large-scale production in accordance with GMP (Good Manufacturing Practice) standards, as well as product quality control and safety assurance.

United States market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Viral Vector-Based Cell & Gene Therapy CDMO players cover AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Viral Vector-Based Cell & Gene Therapy CDMO Industry Forecast” looks at past sales and reviews total world Viral Vector-Based Cell & Gene Therapy CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Viral Vector-Based Cell & Gene Therapy CDMO sales for 2025 through 2031. With Viral Vector-Based Cell & Gene Therapy CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector-Based Cell & Gene Therapy CDMO industry.

This Insight Report provides a comprehensive analysis of the global Viral Vector-Based Cell & Gene Therapy CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector-Based Cell & Gene Therapy CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector-Based Cell & Gene Therapy CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector-Based Cell & Gene Therapy CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector-Based Cell & Gene Therapy CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector-Based Cell & Gene Therapy CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Adeno-associated Viral
    Adenoviral
    Lentiviral
    Retroviral

Segmentation by Application:

    Gene Therapy
    Cell Therapy
    Vaccine Development

This report also splits the market by region:

    Americas

        United States
        Canada
        Mexico
        Brazil

    APAC

        China
        Japan
        Korea
        Southeast Asia
        India
        Australia

    Europe

        Germany
        France
        UK
        Italy
        Russia

    Middle East & Africa

        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    AGC Biologics
    Lonza
    Charles River Laboratories
    Thermo Fisher Scientific
    SK pharmteco
    Exothera